Eliem’s lead drug candidate, ETX-155 is designed to address the high unmet need for new treatments for psychiatric and neurological disorders such as #MDD and #epilepsy, through a clinically validated mechanism of action. Read more about our progress on our website: https://lnkd.in/g2HExg4 #neuronalexcitability
